James Gilchrist
MRCPCH DPhil
NIHR ACADEMIC CLINICAL LECTURER
I am a paediatric registrar, currently undertaking sub-specialty training in paediatric infectious diseases. I completed my DPhil in Oxford with Adrian Hill’s infectious diseases genetics group (Wellcome Centre for Human Genetics) in 2016, supported by a Wellcome Trust Clinical Research Fellowship. My DPhil studies expanded on a long-standing interest in invasive nontyphoidal Salmonella (iNTS) disease in African children and HIV-infected adults, performing a genome-wide association study of iNTS disease in Kenyan and Malawian children alongside functional validation of disease-associated genetic variation.
I joined the Fairfax group in 2018 supported by an NIHR academic clinical lectureship. My current work aims to understand how environmental exposures, in particular CMV infection, interact with genetic determinants of immune cell function and how this interaction modifies health outcomes. I continue to have an active interest in the host genetic determinants of invasive infection in African children, with ongoing collaborative studies investigating the human genetic determinants of leprosy in African populations and rotavirus disease in Kenyan and Ugandan children (supported by an Academy of Medical Sciences Starter Grant for Clinical Lecturers).
Recent publications
-
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Journal article
Taylor CA. et al, (2022), Nat Med
-
BIRC6 modifies risk of invasive bacterial infection in Kenyan children.
Journal article
Gilchrist J. et al, (2022), Elife, 11
-
Natural Killer cells demonstrate distinct eQTL and transcriptome-wide disease associations, highlighting their role in autoimmunity.
Journal article
Gilchrist JJ. et al, (2022), Nat Commun, 13
-
BIRC6 modifies risk of invasive bacterial infection in Kenyan children
Preprint
Gilchrist JJ. et al, (2022)
-
ACTR1A has pleiotropic effects on risk of leprosy, inflammatory bowel disease and atopy
Preprint
Gilchrist JJ. et al, (2022)